Agios Pharmaceuticals, Inc. (AGIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$33.10-0.09%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Agios is launching AQVESME with FDA support, boosting sales. Revenue is expected to grow from about $54 million in 2026 to over $1 billion peak sales. The company has beaten earnings recently, showing improving execution. The stock has gained over 50% in 3 months, reflecting optimism.
Agios remains unprofitable with negative EPS expected through 2027. Revenue growth is uncertain and depends on successful product launches. The company missed earnings in mid-2025 and faces risks in mitapivat's U.S. launch. High valuation and losses pose risks.
The market prices in about 78% revenue growth and values the stock 15% above our fair value near $38. Our fair value is 24% below the Street median, reflecting skepticism on peak sales. We see risk in execution and profitability.
Breaks if: no progress toward $1 billion peak sales over next 3 years
Breaks if: FDA or market issues delay or limit AQVESME launch
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis is cautious, given the company's loss-making status and mixed recent performance.
The market seems to have priced in a low level of fragility, with a justified valuation despite the company's challenges. There is a notable expectations gap, indicating that the market may not fully anticipate the potential risks or rewards ahead.
Fundamentals are likely to remain under pressure due to the company's loss-making nature and recent declines in quality metrics. However, management's focus on launching new products could provide some positive momentum if executed well.
The thesis hinges on several factors, including the success of the U.S. commercial launch of AQVESME and the upcoming FDA decision on mitapivat for sickle cell disease. Additionally, broader healthcare sector performance and economic conditions will play a critical role in AGIO's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens or remains flat beyond FY27
Breaks if: revenue falls below $54 million in FY26
In the next 1 to 3 years, AGIO's performance will depend heavily on its product launches and sector dynamics. Not investment advice.